glp 1 zepbound tirzepatide Study flags need to monitor frailty risks with GLP-1 drugs for older adults Tirzepatide vs Semaglutide: Complete Comparison

The chart below provides guidance for specific situations

The SUSTAIN-6 trial of semaglutide demonstrated a reduction in major adverse cardiovascular events (MACE) in patients with type 2 diabetes and established cardiovascular disease

Berobenatide had a favorable risk-benefit profile with very few adverse events despite the fact that dose deescalation was not allowed in the study. The safety profile of berobenatide in VESPER-2 was consistent with the GLP-1 RA class, and no new safety signals were identified

Check the label before you buy

Dosage adjustments : Using both therapies might require adjustments to dosage to optimize their effectiveness and minimize side effects